Ishita Drugs

Market Cap: Micro Cap
Industry: Pharmaceuticals & Drugs
ISIN: INE806D01016
NSEID:
BSEID: 524400

INR

82.20

-0.5 (-0.6%)

BSENSE

Apr 11, 12:30 PM

BSE+NSE Vol: 170

{
  "main_header": {
    "sid": 444125,
    "name": "Ishita Drugs",
    "stock_name": "Ishita Drugs",
    "full_name": "Ishita Drugs & Industries Ltd",
    "name_url": "stocks-analysis/ishita-drugs",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "82.20",
    "chg": -0.5,
    "chgp": "-0.6%",
    "dir": -1,
    "prev_price": "82.70",
    "mcapval": "24.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524400,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Drugs",
    "ind_code": 4,
    "isin": "INE806D01016",
    "curr_date": "Apr 11, 12:30 PM",
    "curr_time": "01:24 AM",
    "bse_nse_vol": "170 ",
    "exc_status": "Active",
    "traded_date": "Apr 11, 2025",
    "traded_date_str": "2025 04 11",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://sandbox-www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/ishita-drugs-444125-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Ishita Drugs & Industries Adjusts Valuation Grade Amid Strong Market Performance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/ishita-drugs-industries-valuation-grade-downgraded-from-attractive-to-fair-3-1669850",
        "imagepath": "",
        "date": "2025-04-02 08:00:58",
        "description": "Ishita Drugs & Industries has recently undergone a valuation adjustment, reflecting a reassessment of its financial metrics within the pharmaceuticals and drugs sector. The company currently exhibits a price-to-earnings (P/E) ratio of 24.74 and a price-to-book value of 2.49. Its enterprise value to EBITDA stands at 16.53, while the enterprise value to EBIT is recorded at 16.86. The PEG ratio is noted at 0.77, indicating a particular valuation perspective.\n\nIn terms of performance, Ishita Drugs has demonstrated a notable return over various periods, with a one-year return of 21.68%, significantly outperforming the Sensex, which returned 2.72% in the same timeframe. Over a five-year span, the company has achieved an impressive return of 655.53%, compared to the Sensex's 168.97%.\n\nWhen compared to its peers, Ishita Drugs maintains a competitive position, particularly against companies like Kwality Pharma and K..."
      },
      {
        "title": "Ishita Drugs Faces Evaluation Shift Amid Mixed Technical Indicators and Valuation Concerns",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/ishita-drugs-industries-stock-downgraded-to-strong-sell-amid-bearish-trends-1619709",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/3/IshitaDrugsIndu_mojoScore_815188.png",
        "date": "2025-03-27 08:03:03",
        "description": "Ishita Drugs & Industries has experienced a recent evaluation adjustment, reflecting shifts in its financial metrics and market position. The company's valuation has been revised, indicating a transition in its market stance, while key technical indicators suggest a mixed outlook amid pressures on long-term fundamentals."
      },
      {
        "title": "Ishita Drugs & Industries Adjusts Valuation Amid Strong Performance in Pharmaceuticals Sector",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/ishita-drugs-industries-valuation-grade-downgraded-from-attractive-to-fair-1619509",
        "imagepath": "",
        "date": "2025-03-27 08:00:16",
        "description": "Ishita Drugs & Industries, a microcap player in the Pharmaceuticals & Drugs sector, has recently undergone a valuation adjustment. The company's current price stands at 81.30, reflecting a notable increase from the previous close of 77.09. Over the past year, Ishita Drugs has demonstrated a stock return of 29.48%, significantly outperforming the Sensex, which recorded a return of 6.65% during the same period.\n\nKey financial metrics for Ishita Drugs include a PE ratio of 24.31 and an EV to EBITDA ratio of 16.11. The company's return on capital employed (ROCE) is reported at an impressive 39.71%, while the return on equity (ROE) stands at 8.67%. These figures indicate a solid operational performance relative to its peers.\n\nIn comparison to other companies in the industry, Ishita Drugs maintains a competitive position. For instance, Shukra Pharma is noted for its high valuation metrics, while companies like Ko..."
      },
      {
        "title": "Ishita Drugs & Industries Adjusts Valuation Amid Competitive Pharmaceuticals Landscape",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/ishita-drugs-industries-sees-valuation-grade-downgrade-from-attractive-to-fair-279-1463271",
        "imagepath": "",
        "date": "2025-03-19 08:00:18",
        "description": "Ishita Drugs & Industries, a microcap player in the pharmaceuticals and drugs sector, has recently undergone a valuation adjustment. The company currently exhibits a price-to-earnings (P/E) ratio of 23.62 and a price-to-book value of 2.38. Its enterprise value to EBITDA stands at 15.43, while the enterprise value to EBIT is recorded at 15.74. The PEG ratio is noted at 0.74, indicating a favorable growth perspective relative to its earnings.\n\nIn terms of performance metrics, Ishita Drugs boasts a return on capital employed (ROCE) of 39.71% and a return on equity (ROE) of 8.67%. These figures reflect the company's operational efficiency and profitability.\n\nWhen compared to its peers, Ishita Drugs holds a competitive position. For instance, Shree Ganesh Remedies is noted for its higher valuation metrics, while companies like Anuh Pharma and Kopran present attractive alternatives with lower P/E ratios. This con..."
      },
      {
        "title": "Ishita Drugs & Industries Faces Market Reassessment Amid Flat Financial Performance",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/ishita-drugs-industries-receives-sell-upgrade-amid-flat-financial-performance-1423437",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/3/IshitaDrugsIndu_mojoScore_682518.png",
        "date": "2025-03-18 08:06:44",
        "description": "Ishita Drugs & Industries has recently experienced a score adjustment following a reassessment of its market position in the pharmaceuticals sector. The company reported flat financial performance for the quarter ending December 2024, with modest growth in net sales and operating profit, alongside challenges in debt management."
      },
      {
        "title": "Ishita Drugs Adjusts Valuation Amidst Competitive Pharmaceutical Sector Landscape",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/ishita-drugs-industries-sees-valuation-grade-downgrade-from-attractive-to-fair-277-1371881",
        "imagepath": "",
        "date": "2025-03-13 08:00:21",
        "description": "Ishita Drugs & Industries has recently undergone a valuation adjustment, reflecting its current standing in the pharmaceuticals and drugs sector. The company's price-to-earnings (PE) ratio stands at 23.56, while its price-to-book value is recorded at 2.38. Other key metrics include an EV to EBIT ratio of 15.68 and an EV to EBITDA ratio of 15.38, indicating its operational efficiency relative to its enterprise value.\n\nIn terms of return on capital employed (ROCE), Ishita Drugs boasts a notable figure of 39.71%, alongside a return on equity (ROE) of 8.67%. These metrics suggest a solid performance in generating returns from its capital investments.\n\nWhen compared to its peers, Ishita Drugs presents a competitive valuation landscape. For instance, Shree Ganesh Rem is positioned at a higher valuation, while Anuh Pharma stands out with a more attractive valuation profile. Other competitors like Kopran and Fermen..."
      },
      {
        "title": "Ishita Drugs Adjusts Valuation Amidst Competitive Pharmaceutical Sector Landscape",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/ishita-drugs-industries-sees-valuation-grade-downgrade-from-attractive-to-fair-2-1360299",
        "imagepath": "",
        "date": "2025-03-13 08:00:21",
        "description": "Ishita Drugs & Industries has recently undergone a valuation adjustment, reflecting its current standing in the pharmaceuticals and drugs sector. The company's price-to-earnings (PE) ratio stands at 23.56, while its price-to-book value is recorded at 2.38. Other key metrics include an EV to EBIT ratio of 15.68 and an EV to EBITDA ratio of 15.38, indicating its operational efficiency relative to its enterprise value.\n\nIn terms of return on capital employed (ROCE), Ishita Drugs boasts a notable figure of 39.71%, alongside a return on equity (ROE) of 8.67%. These metrics suggest a solid performance in generating returns from its capital investments.\n\nWhen compared to its peers, Ishita Drugs presents a competitive valuation landscape. For instance, Shree Ganesh Rem is positioned at a higher valuation, while Anuh Pharma stands out with a more attractive valuation profile. Other competitors like Kopran and Fermen..."
      },
      {
        "title": "Ishita Drugs & Industries Faces Financial Reassessment Amid Modest Growth and Debt Concerns",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/ishita-drugs-industries-stock-downgraded-to-strong-sell-amid-flat-financial-performance-1301930",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/3/IshitaDrugsIndu_mojoScore_653364.png",
        "date": "2025-03-12 08:01:45",
        "description": "Ishita Drugs & Industries has recently adjusted its evaluation, reflecting a reassessment of its financial position in the pharmaceuticals sector. The company reported flat performance for Q3 FY24-25, with modest growth over five years and concerns regarding debt management, despite maintaining an attractive valuation and outperforming the BSE 500."
      },
      {
        "title": "Ishita Drugs & Industries Adjusts Valuation Amid Competitive Pharmaceutical Landscape",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/ishita-drugs-industries-sees-valuation-grade-shift-from-attractive-to-fair-1213101",
        "imagepath": "",
        "date": "2025-03-06 08:00:30",
        "description": "Ishita Drugs & Industries has recently undergone a valuation adjustment, reflecting its current standing in the pharmaceuticals and drugs sector. The company, classified as a microcap, has reported a price-to-earnings (P/E) ratio of 24.52 and an enterprise value to EBITDA ratio of 16.31. These metrics indicate a competitive positioning within its industry, particularly when compared to peers.\n\nIn terms of financial performance, Ishita Drugs boasts a return on capital employed (ROCE) of 39.71% and a return on equity (ROE) of 8.67%. These figures suggest a solid operational efficiency relative to its market segment. The company's stock has shown varied performance over different time frames, with a notable 15.36% return over the past year, significantly outperforming the Sensex, which recorded a mere 0.07% return in the same period.\n\nWhen compared to its peers, Ishita Drugs presents a more favorable valuation..."
      }
    ],
    "total": 32,
    "sid": "444125",
    "stock_news_url": "https://sandbox-www.marketsmojo.com/news/ishita-drugs-industries-444125"
  },
  "announcements": [
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "09-Apr-2025",
      "details": "We submit herewith the confirmation certificate received from M/s Bigshare Services Private Limited RTA as per Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018 for the quarter ended 31st March 2025.",
      "source": "BSE"
    },
    {
      "caption": "Closure of Trading Window",
      "datetime": "19-Mar-2025",
      "details": "The Trading window for dealing in securities of the Company by Designated Persons stands closed from Tuesday 1st April 2025 till 48 hours after the declaration of the Audited Financial Results for the quarter and financial year ended 31st March 2025",
      "source": "BSE"
    },
    {
      "caption": "Disclosure Under Regulation 29(2) Of SEBI (Substantial Acquisition Of Shares And Takeovers) Regulations 2011",
      "datetime": "01-Mar-2025",
      "details": "Disclosure under regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations 2011 received from Jagdish Agrawal",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Ishita Drugs & Industries Adjusts Valuation Grade Amid Strong Market Performance

2025-04-02 08:00:58

Ishita Drugs & Industries has recently undergone a valuation adjustment, reflecting a reassessment of its financial metrics within the pharmaceuticals and drugs sector. The company currently exhibits a price-to-earnings (P/E) ratio of 24.74 and a price-to-book value of 2.49. Its enterprise value to EBITDA stands at 16.53, while the enterprise value to EBIT is recorded at 16.86. The PEG ratio is noted at 0.77, indicating a particular valuation perspective. In terms of performance, Ishita Drugs has demonstrated a notable return over various periods, with a one-year return of 21.68%, significantly outperforming the Sensex, which returned 2.72% in the same timeframe. Over a five-year span, the company has achieved an impressive return of 655.53%, compared to the Sensex's 168.97%. When compared to its peers, Ishita Drugs maintains a competitive position, particularly against companies like Kwality Pharma and K...

Ishita Drugs Faces Evaluation Shift Amid Mixed Technical Indicators and Valuation Concerns

2025-03-27 08:03:03

Ishita Drugs & Industries has experienced a recent evaluation adjustment, reflecting shifts in its financial metrics and market position. The company's valuation has been revised, indicating a transition in its market stance, while key technical indicators suggest a mixed outlook amid pressures on long-term fundamentals.

Ishita Drugs & Industries Adjusts Valuation Amid Strong Performance in Pharmaceuticals Sector

2025-03-27 08:00:16

Ishita Drugs & Industries, a microcap player in the Pharmaceuticals & Drugs sector, has recently undergone a valuation adjustment. The company's current price stands at 81.30, reflecting a notable increase from the previous close of 77.09. Over the past year, Ishita Drugs has demonstrated a stock return of 29.48%, significantly outperforming the Sensex, which recorded a return of 6.65% during the same period. Key financial metrics for Ishita Drugs include a PE ratio of 24.31 and an EV to EBITDA ratio of 16.11. The company's return on capital employed (ROCE) is reported at an impressive 39.71%, while the return on equity (ROE) stands at 8.67%. These figures indicate a solid operational performance relative to its peers. In comparison to other companies in the industry, Ishita Drugs maintains a competitive position. For instance, Shukra Pharma is noted for its high valuation metrics, while companies like Ko...

Ishita Drugs & Industries Adjusts Valuation Amid Competitive Pharmaceuticals Landscape

2025-03-19 08:00:18

Ishita Drugs & Industries, a microcap player in the pharmaceuticals and drugs sector, has recently undergone a valuation adjustment. The company currently exhibits a price-to-earnings (P/E) ratio of 23.62 and a price-to-book value of 2.38. Its enterprise value to EBITDA stands at 15.43, while the enterprise value to EBIT is recorded at 15.74. The PEG ratio is noted at 0.74, indicating a favorable growth perspective relative to its earnings. In terms of performance metrics, Ishita Drugs boasts a return on capital employed (ROCE) of 39.71% and a return on equity (ROE) of 8.67%. These figures reflect the company's operational efficiency and profitability. When compared to its peers, Ishita Drugs holds a competitive position. For instance, Shree Ganesh Remedies is noted for its higher valuation metrics, while companies like Anuh Pharma and Kopran present attractive alternatives with lower P/E ratios. This con...

Ishita Drugs & Industries Faces Market Reassessment Amid Flat Financial Performance

2025-03-18 08:06:44

Ishita Drugs & Industries has recently experienced a score adjustment following a reassessment of its market position in the pharmaceuticals sector. The company reported flat financial performance for the quarter ending December 2024, with modest growth in net sales and operating profit, alongside challenges in debt management.

Ishita Drugs Adjusts Valuation Amidst Competitive Pharmaceutical Sector Landscape

2025-03-13 08:00:21

Ishita Drugs & Industries has recently undergone a valuation adjustment, reflecting its current standing in the pharmaceuticals and drugs sector. The company's price-to-earnings (PE) ratio stands at 23.56, while its price-to-book value is recorded at 2.38. Other key metrics include an EV to EBIT ratio of 15.68 and an EV to EBITDA ratio of 15.38, indicating its operational efficiency relative to its enterprise value. In terms of return on capital employed (ROCE), Ishita Drugs boasts a notable figure of 39.71%, alongside a return on equity (ROE) of 8.67%. These metrics suggest a solid performance in generating returns from its capital investments. When compared to its peers, Ishita Drugs presents a competitive valuation landscape. For instance, Shree Ganesh Rem is positioned at a higher valuation, while Anuh Pharma stands out with a more attractive valuation profile. Other competitors like Kopran and Fermen...

Ishita Drugs Adjusts Valuation Amidst Competitive Pharmaceutical Sector Landscape

2025-03-13 08:00:21

Ishita Drugs & Industries Faces Financial Reassessment Amid Modest Growth and Debt Concerns

2025-03-12 08:01:45

Ishita Drugs & Industries has recently adjusted its evaluation, reflecting a reassessment of its financial position in the pharmaceuticals sector. The company reported flat performance for Q3 FY24-25, with modest growth over five years and concerns regarding debt management, despite maintaining an attractive valuation and outperforming the BSE 500.

Ishita Drugs & Industries Adjusts Valuation Amid Competitive Pharmaceutical Landscape

2025-03-06 08:00:30

Ishita Drugs & Industries has recently undergone a valuation adjustment, reflecting its current standing in the pharmaceuticals and drugs sector. The company, classified as a microcap, has reported a price-to-earnings (P/E) ratio of 24.52 and an enterprise value to EBITDA ratio of 16.31. These metrics indicate a competitive positioning within its industry, particularly when compared to peers. In terms of financial performance, Ishita Drugs boasts a return on capital employed (ROCE) of 39.71% and a return on equity (ROE) of 8.67%. These figures suggest a solid operational efficiency relative to its market segment. The company's stock has shown varied performance over different time frames, with a notable 15.36% return over the past year, significantly outperforming the Sensex, which recorded a mere 0.07% return in the same period. When compared to its peers, Ishita Drugs presents a more favorable valuation...

View All News

Announcement

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018

09-Apr-2025 | Source : BSE

We submit herewith the confirmation certificate received from M/s Bigshare Services Private Limited RTA as per Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018 for the quarter ended 31st March 2025.

Closure of Trading Window

19-Mar-2025 | Source : BSE

The Trading window for dealing in securities of the Company by Designated Persons stands closed from Tuesday 1st April 2025 till 48 hours after the declaration of the Audited Financial Results for the quarter and financial year ended 31st March 2025